260 related articles for article (PubMed ID: 28270509)
41. T Cell Activation Pathways: B7, LFA-3, and ICAM-1 Shape Unique T Cell Profiles.
Wingren AG; Parra E; Varga M; Kalland T; Sjogren HO; Hedlund G; Dohlsten M
Crit Rev Immunol; 2017; 37(2-6):463-481. PubMed ID: 29773030
[TBL] [Abstract][Full Text] [Related]
42. Programmed death receptor 1 (PD-1) ligand Fc fusion proteins reduce T-cell proliferation in vitro independently of PD-1.
Biemond M; Vremec D; Gray DH; Hodgkin PD; Heinzel S
Immunol Cell Biol; 2024 Feb; 102(2):117-130. PubMed ID: 38069638
[TBL] [Abstract][Full Text] [Related]
43. Clinical Value of the PD-1/PD-L1/PD-L2 Pathway in Patients Suffering from Endometriosis.
Suszczyk D; Skiba W; Zardzewiały W; Pawłowska A; Włodarczyk K; Polak G; Tarkowski R; Wertel I
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36232911
[TBL] [Abstract][Full Text] [Related]
44. Crystal structure of the complex between programmed death-1 (PD-1) and its ligand PD-L2.
Lázár-Molnár E; Yan Q; Cao E; Ramagopal U; Nathenson SG; Almo SC
Proc Natl Acad Sci U S A; 2008 Jul; 105(30):10483-8. PubMed ID: 18641123
[TBL] [Abstract][Full Text] [Related]
45. Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells.
Goldberg MV; Maris CH; Hipkiss EL; Flies AS; Zhen L; Tuder RM; Grosso JF; Harris TJ; Getnet D; Whartenby KA; Brockstedt DG; Dubensky TW; Chen L; Pardoll DM; Drake CG
Blood; 2007 Jul; 110(1):186-92. PubMed ID: 17392506
[TBL] [Abstract][Full Text] [Related]
46. B7-DC-Ig enhances vaccine effect by a novel mechanism dependent on PD-1 expression level on T cell subsets.
Mkrtichyan M; Najjar YG; Raulfs EC; Liu L; Langerman S; Guittard G; Ozbun L; Khleif SN
J Immunol; 2012 Sep; 189(5):2338-47. PubMed ID: 22837483
[TBL] [Abstract][Full Text] [Related]
47. Human brain endothelial cells endeavor to immunoregulate CD8 T cells via PD-1 ligand expression in multiple sclerosis.
Pittet CL; Newcombe J; Prat A; Arbour N
J Neuroinflammation; 2011 Nov; 8():155. PubMed ID: 22067141
[TBL] [Abstract][Full Text] [Related]
48. The structural features that distinguish PD-L2 from PD-L1 emerged in placental mammals.
Philips EA; Garcia-España A; Tocheva AS; Ahearn IM; Adam KR; Pan R; Mor A; Kong XP
J Biol Chem; 2020 Apr; 295(14):4372-4380. PubMed ID: 31882544
[TBL] [Abstract][Full Text] [Related]
49. Impairment of the programmed cell death-1 pathway increases atherosclerotic lesion development and inflammation.
Bu DX; Tarrio M; Maganto-Garcia E; Stavrakis G; Tajima G; Lederer J; Jarolim P; Freeman GJ; Sharpe AH; Lichtman AH
Arterioscler Thromb Vasc Biol; 2011 May; 31(5):1100-7. PubMed ID: 21393583
[TBL] [Abstract][Full Text] [Related]
50. PD-1 as an immune modulatory receptor.
Yao S; Chen L
Cancer J; 2014; 20(4):262-4. PubMed ID: 25098286
[TBL] [Abstract][Full Text] [Related]
51. Expression of PD-L1 and PD-L2 on human macrophages is up-regulated by HIV-1 and differentially modulated by IL-10.
Rodríguez-García M; Porichis F; de Jong OG; Levi K; Diefenbach TJ; Lifson JD; Freeman GJ; Walker BD; Kaufmann DE; Kavanagh DG
J Leukoc Biol; 2011 Apr; 89(4):507-15. PubMed ID: 21097698
[TBL] [Abstract][Full Text] [Related]
52. Soluble CD80 Protein Delays Tumor Growth and Promotes Tumor-Infiltrating Lymphocytes.
Horn LA; Long TM; Atkinson R; Clements V; Ostrand-Rosenberg S
Cancer Immunol Res; 2018 Jan; 6(1):59-68. PubMed ID: 29122838
[TBL] [Abstract][Full Text] [Related]
53. Analysis of the role of negative T cell costimulatory pathways in CD4 and CD8 T cell-mediated alloimmune responses in vivo.
Ito T; Ueno T; Clarkson MR; Yuan X; Jurewicz MM; Yagita H; Azuma M; Sharpe AH; Auchincloss H; Sayegh MH; Najafian N
J Immunol; 2005 Jun; 174(11):6648-56. PubMed ID: 15905503
[TBL] [Abstract][Full Text] [Related]
54. Identification, binding, and structural characterization of single domain anti-PD-L1 antibodies inhibitory of immune regulatory proteins PD-1 and CD80.
Kang-Pettinger T; Walker K; Brown R; Cowan R; Wright H; Baravalle R; Waters LC; Muskett FW; Bowler MW; Sawmynaden K; Coombs PJ; Carr MD; Hall G
J Biol Chem; 2023 Jan; 299(1):102769. PubMed ID: 36470427
[TBL] [Abstract][Full Text] [Related]
55. Understanding the structural and energetic basis of PD-1 and monoclonal antibodies bound to PD-L1: A molecular modeling perspective.
Shi D; Zhou S; Liu X; Zhao C; Liu H; Yao X
Biochim Biophys Acta Gen Subj; 2018 Mar; 1862(3):576-588. PubMed ID: 29203283
[TBL] [Abstract][Full Text] [Related]
56. A theoretical framework for quantitative analysis of the molecular basis of costimulation.
Jansson A; Barnes E; Klenerman P; Harlén M; Sørensen P; Davis SJ; Nilsson P
J Immunol; 2005 Aug; 175(3):1575-85. PubMed ID: 16034096
[TBL] [Abstract][Full Text] [Related]
57. Symmetry-based ligand design and evaluation of small molecule inhibitors of programmed cell death-1/programmed death-ligand 1 interaction.
Kawashita S; Aoyagi K; Yamanaka H; Hantani R; Naruoka S; Tanimoto A; Hori Y; Toyonaga Y; Fukushima K; Miyazaki S; Hantani Y
Bioorg Med Chem Lett; 2019 Sep; 29(17):2464-2467. PubMed ID: 31351692
[TBL] [Abstract][Full Text] [Related]
58. Role of the programmed death-1 pathway in regulation of alloimmune responses in vivo.
Sandner SE; Clarkson MR; Salama AD; Sanchez-Fueyo A; Domenig C; Habicht A; Najafian N; Yagita H; Azuma M; Turka LA; Sayegh MH
J Immunol; 2005 Mar; 174(6):3408-15. PubMed ID: 15749874
[TBL] [Abstract][Full Text] [Related]
59. Failure to upregulate cell surface PD-1 is associated with dysregulated stimulation of T cells by TGN1412-like CD28 superagonist.
Thaventhiran T; Alhumeed N; Yeang HX; Sethu S; Downey JS; Alghanem AF; Olayanju A; Smith EL; Cross MJ; Webb SD; Williams DP; Bristow A; Ball C; Stebbings R; Sathish JG
MAbs; 2014; 6(5):1290-9. PubMed ID: 25517314
[TBL] [Abstract][Full Text] [Related]
60. Discovery of Novel Small-Molecule Inhibitors of PD-1/PD-L1 Interaction via Structural Simplification Strategy.
Zhang H; Xia Y; Yu C; Du H; Liu J; Li H; Huang S; Zhu Q; Xu Y; Zou Y
Molecules; 2021 Jun; 26(11):. PubMed ID: 34199417
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
